[18F]FDG-PET/CT in Hodgkin Lymphoma: Current Usefulness and Perspectives
AbstractFunctional imaging using 18-fluorodeoxyglycose ([18F]FDG) positron emission tomography combined with computed tomography (PET/CT) has become a major imaging modality in Hodgkin lymphoma. This imaging modality allows for a significant improvement in staging, increased sensitivity, which involves differentiating residual tumors from fibrosis during assessment, and highly impacts treatment decisions into new PET-driven strategies. This review presents the main scientific data concerning the current applications of [18F]FDG-PET/CT in Hodgkin lymphoma at baseline, interim, and the end of treatment evaluation along with the main PET-driven trials for therapeutic decisions. The emergence of total metabolic tumor volume as a new functional prognostic factor will also be discussed. View Full-Text
Share & Cite This Article
Kanoun, S.; Rossi, C.; Casasnovas, O. [18F]FDG-PET/CT in Hodgkin Lymphoma: Current Usefulness and Perspectives. Cancers 2018, 10, 145.
Kanoun S, Rossi C, Casasnovas O. [18F]FDG-PET/CT in Hodgkin Lymphoma: Current Usefulness and Perspectives. Cancers. 2018; 10(5):145.Chicago/Turabian Style
Kanoun, Salim; Rossi, Cedric; Casasnovas, Olivier. 2018. "[18F]FDG-PET/CT in Hodgkin Lymphoma: Current Usefulness and Perspectives." Cancers 10, no. 5: 145.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.